{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:14:10Z","timestamp":1793830450032,"version":"4.6.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Key R&D Program of China","award":["2020YFA0710803"],"award-info":[{"award-number":["2020YFA0710803"]}]},{"name":"the National Key R&D Program of China","award":["2017YFA0105704"],"award-info":[{"award-number":["2017YFA0105704"]}]},{"name":"National Natural Science Foundation of China (NSFC) grants","award":["81900570"],"award-info":[{"award-number":["81900570"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China (NSFC) grants","award":["81700569"],"award-info":[{"award-number":["81700569"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China (NSFC) grants","award":["81870421"],"award-info":[{"award-number":["81870421"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China (NSFC) grants","award":["82030001"],"award-info":[{"award-number":["82030001"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China (NSFC) grants","award":["81873562"],"award-info":[{"award-number":["81873562"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Funds for International Cooperation and Exchange of the National Natural Science Foundation of China","award":["81820108005"],"award-info":[{"award-number":["81820108005"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002858","name":"the China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2019M653966"],"award-info":[{"award-number":["2019M653966"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mesenchymal stem cell (MSC) therapy has been shown to be a promising option for liver fibrosis treatment. However, critical factors affecting the efficacy of MSC therapy for liver fibrosis remain unknown. Follistatin-like 1 (FSTL1), a TGF-\u03b2-induced matricellular protein, is documented as an intrinsic regulator of proliferation and differentiation in MSCs. In the present study, we characterized the potential role of FSTL1 in MSC-based anti-fibrotic therapy and further elucidated the mechanisms underlying its action.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Human\u00a0umbilical cord-derived MSCs were characterized by flow cytometry. FSTL1\n                      <jats:sup>low<\/jats:sup>\n                      MSCs were achieved by FSTL1 siRNA. Migration capacity was evaluated by wound-healing and transwell assay. A murine liver fibrotic model was created by carbon tetrachloride (CCl\n                      <jats:sub>4<\/jats:sub>\n                      ) injection, while control MSCs or FSTL1\n                      <jats:sup>low<\/jats:sup>\n                      MSC were transplanted via intravenous injection 12\u00a0weeks post CCl\n                      <jats:sub>4<\/jats:sub>\n                      injection. Histopathology, liver function, fibrosis degree, and inflammation were analysed thereafter. Inflammatory cell infiltration was evaluated by flow cytometry after hepatic nonparenchymal\u00a0cell isolation. An MSC-macrophage co-culture system was constructed to further confirm the role of FSTL1 in the immunosuppressive capacity of MSCs. RNA sequencing was used to screen target genes of FSTL1.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      FSTL1\n                      <jats:sup>low<\/jats:sup>\n                      MSCs had comparable gene\u00a0expression for surface markers to wildtype but limited differentiation and migration capacity. FSTL1\n                      <jats:sup>low<\/jats:sup>\n                      MSCs failed to alleviate CCl\n                      <jats:sub>4<\/jats:sub>\n                      -induced hepatic fibrosis in a mouse model. Our data indicated that FSTL1 is essential for the immunosuppressive action of MSCs on inflammatory macrophages during liver fibrotic therapy. FSTL1 silencing attenuated this capacity by inhibiting the downstream JAK\/STAT1\/IDO pathway.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data suggest that FSTL1 facilitates the immunosuppression of MSCs on macrophages and that guarantee the anti-fibrotic effect of MSCs in liver fibrosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-022-03042-4","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T08:21:39Z","timestamp":1659687699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Endogenous Follistatin-like 1 guarantees the immunomodulatory properties of mesenchymal stem cells during liver fibrotic therapy"],"prefix":"10.1186","volume":"13","author":[{"given":"Xiaohong","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuoyi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheyi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boquan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3046-9507","authenticated-orcid":false,"given":"Ying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"issue":"3","key":"3042_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","volume":"5","author":"GBDC Collaborators","year":"2020","unstructured":"Collaborators GBDC. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):245\u201366.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"3042_CR2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/cld.1061","volume":"17","author":"S Cheemerla","year":"2021","unstructured":"Cheemerla S, Balakrishnan M. Global epidemiology of chronic liver disease. Clin Liver Dis (Hoboken). 2021;17(5):365\u201370.","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"2","key":"3042_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S2468-1253(19)30342-5","volume":"5","author":"SK Sarin","year":"2020","unstructured":"Sarin SK, et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2020;5(2):167\u2013228.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"3042_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/S2468-1253(16)30110-8","volume":"1","author":"P Ramachandran","year":"2016","unstructured":"Ramachandran P, Henderson NC. Antifibrotics in chronic liver disease: tractable targets and translational challenges. Lancet Gastroenterol Hepatol. 2016;1(4):328\u201340.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 2","key":"3042_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1440-1746.2011.07024.x","volume":"27","author":"Z Zhang","year":"2012","unstructured":"Zhang Z, et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J Gastroenterol Hepatol. 2012;27(Suppl 2):112\u201320.","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"3042_CR6","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.jhep.2018.01.030","volume":"68","author":"M Alfaifi","year":"2018","unstructured":"Alfaifi M, et al. Mesenchymal stromal cell therapy for liver diseases. J Hepatol. 2018;68(6):1272\u201385.","journal-title":"J Hepatol"},{"issue":"1","key":"3042_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jhep.2020.09.014","volume":"74","author":"BJ Dwyer","year":"2021","unstructured":"Dwyer BJ, et al. Cell therapy for advanced liver diseases: repair or rebuild. J Hepatol. 2021;74(1):185\u201399.","journal-title":"J Hepatol"},{"issue":"3","key":"3042_CR8","first-page":"381","volume":"16","author":"AJ Friedenstein","year":"1966","unstructured":"Friedenstein AJ, Piatetzky S II, Petrakova KV. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol. 1966;16(3):381\u201390.","journal-title":"J Embryol Exp Morphol"},{"key":"3042_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.655268","volume":"8","author":"Y Yang","year":"2021","unstructured":"Yang Y, et al. The application of mesenchymal stem cells in the treatment of liver diseases: mechanism, efficacy, and safety issues. Front Med. 2021;8: 655268.","journal-title":"Front Med"},{"issue":"4","key":"3042_CR10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.stem.2013.09.006","volume":"13","author":"ME Bernardo","year":"2013","unstructured":"Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392\u2013402.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"3042_CR11","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1002\/hep.26754","volume":"59","author":"A Sica","year":"2014","unstructured":"Sica A, Invernizzi P, Mantovani A. Macrophage plasticity and polarization in liver homeostasis and pathology. Hepatology. 2014;59(5):2034\u201342.","journal-title":"Hepatology"},{"issue":"1","key":"3042_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1172\/JCI88881","volume":"127","author":"Y Koyama","year":"2017","unstructured":"Koyama Y, Brenner DA. Liver inflammation and fibrosis. J Clin Invest. 2017;127(1):55\u201364.","journal-title":"J Clin Invest"},{"issue":"1","key":"3042_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1432-1033.1993.tb18212.x","volume":"217","author":"M Shibanuma","year":"1993","unstructured":"Shibanuma M, et al. Cloning from a mouse osteoblastic cell line of a set of transforming-growth-factor-beta 1-regulated genes, one of which seems to encode a follistatin-related polypeptide. Eur J Biochem. 1993;217(1):13\u20139.","journal-title":"Eur J Biochem"},{"issue":"2","key":"3042_CR14","doi-asserted-by":"publisher","first-page":"L240","DOI":"10.1152\/ajplung.00523.2016","volume":"313","author":"X Zheng","year":"2017","unstructured":"Zheng X, et al. TGF-beta1 induces Fstl1 via the Smad3-c-Jun pathway in lung fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2017;313(2):L240\u201351.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"3042_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/bdrc.21030","volume":"99","author":"M Sylva","year":"2013","unstructured":"Sylva M, Moorman AF, van den Hoff MJ. Follistatin-like 1 in vertebrate development. Birth Defects Res C Embryo Today. 2013;99(1):61\u20139.","journal-title":"Birth Defects Res C Embryo Today"},{"issue":"1\u20133","key":"3042_CR16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s12026-014-8526-z","volume":"59","author":"Y Chaly","year":"2014","unstructured":"Chaly Y, et al. Follistatin-like protein 1 and its role in inflammation and inflammatory diseases. Immunol Res. 2014;59(1\u20133):266\u201372.","journal-title":"Immunol Res"},{"issue":"4","key":"3042_CR17","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/art.33422","volume":"64","author":"Y Chaly","year":"2012","unstructured":"Chaly Y, et al. FSTL1 promotes arthritis in mice by enhancing inflammatory cytokine\/chemokine expression. Arthritis Rheum. 2012;64(4):1082\u20138.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"3042_CR18","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1136\/annrheumdis-2013-204822","volume":"74","author":"Y Chaly","year":"2015","unstructured":"Chaly Y, et al. Follistatin-like protein 1 regulates chondrocyte proliferation and chondrogenic differentiation of mesenchymal stem cells. Ann Rheum Dis. 2015;74(7):1467\u201373.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3042_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13287-018-1111-y","volume":"10","author":"H Shen","year":"2019","unstructured":"Shen H, et al. Follistatin-like 1 protects mesenchymal stem cells from hypoxic damage and enhances their therapeutic efficacy in a mouse myocardial infarction model. Stem Cell Res Ther. 2019;10(1):17.","journal-title":"Stem Cell Res Ther"},{"issue":"25","key":"3042_CR20","first-page":"2017","volume":"96","author":"MQ Zhang","year":"2016","unstructured":"Zhang MQ, et al. Follistatin-like 1-engineered mesenchymal stem cells prevent myocardial ischemic reperfusion injury. Zhonghua Yi Xue Za Zhi. 2016;96(25):2017\u201322.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"1","key":"3042_CR21","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/cells9010212","volume":"9","author":"JH Kim","year":"2020","unstructured":"Kim JH, et al. Characterization of mesenchymal stem cells derived from patients with cerebellar ataxia: downregulation of the anti-inflammatory secretome profile. Cells. 2020;9(1):212.","journal-title":"Cells"},{"key":"3042_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325150","author":"J Rao","year":"2022","unstructured":"Rao J, et al. FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2. Gut. 2022. https:\/\/doi.org\/10.1136\/gutjnl-2021-325150.","journal-title":"Gut"},{"issue":"1","key":"3042_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12964-020-00610-0","volume":"18","author":"XY Xu","year":"2020","unstructured":"Xu XY, et al. Targeting Follistatin like 1 ameliorates liver fibrosis induced by carbon tetrachloride through TGF-beta1-miR29a in mice. Cell Commun Signal. 2020;18(1):151.","journal-title":"Cell Commun Signal"},{"key":"3042_CR24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.omtn.2017.04.014","volume":"7","author":"EH Vollmann","year":"2017","unstructured":"Vollmann EH, et al. Identification of Novel Fibrosis Modifiers by In Vivo siRNA Silencing. Mol Ther Nucleic Acids. 2017;7:314\u201323.","journal-title":"Mol Ther Nucleic Acids"},{"key":"3042_CR25","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120274","author":"D Ramnath","year":"2018","unstructured":"Ramnath D, et al. Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes. JCI Insight. 2018. https:\/\/doi.org\/10.1172\/jci.insight.120274.","journal-title":"JCI Insight"},{"issue":"2","key":"3042_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1084\/jem.20121878","volume":"212","author":"Y Dong","year":"2015","unstructured":"Dong Y, et al. Blocking follistatin-like 1 attenuates bleomycin-induced pulmonary fibrosis in mice. J Exp Med. 2015;212(2):235\u201352.","journal-title":"J Exp Med"},{"issue":"24","key":"3042_CR27","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1161\/CIRCULATIONAHA.108.767673","volume":"117","author":"Y Oshima","year":"2008","unstructured":"Oshima Y, et al. Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart. Circulation. 2008;117(24):3099\u2013108.","journal-title":"Circulation"},{"issue":"1","key":"3042_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41598-018-37184-4","volume":"9","author":"LY Ghanem","year":"2019","unstructured":"Ghanem LY, et al. Liver macrophage depletion ameliorates the effect of mesenchymal stem cell transplantation in a murine model of injured liver. Sci Rep. 2019;9(1):35.","journal-title":"Sci Rep"},{"issue":"1","key":"3042_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/mt.2011.189","volume":"20","author":"M Francois","year":"2012","unstructured":"Francois M, et al. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther. 2012;20(1):187\u201395.","journal-title":"Mol Ther"},{"issue":"1","key":"3042_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41419-020-03277-0","volume":"12","author":"C Mo","year":"2021","unstructured":"Mo C, et al. Indoleamine 2,3-dioxygenase 1 limits hepatic inflammatory cells recruitment and promotes bile duct ligation-induced liver fibrosis. Cell Death Dis. 2021;12(1):16.","journal-title":"Cell Death Dis"},{"issue":"8","key":"3042_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1167\/iovs.61.8.28","volume":"61","author":"N Jiang","year":"2020","unstructured":"Jiang N, et al. Indoleamine 2,3-dioxygenase regulates macrophage recruitment, polarization and phagocytosis in aspergillus fumigatus keratitis. Invest Ophthalmol Vis Sci. 2020;61(8):28.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1\u20132","key":"3042_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cellimm.2014.02.005","volume":"289","author":"XF Wang","year":"2014","unstructured":"Wang XF, et al. The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: focus on macrophage polarization of THP-1 cells. Cell Immunol. 2014;289(1\u20132):42\u20138.","journal-title":"Cell Immunol"},{"issue":"1","key":"3042_CR33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2017.09.049","volume":"154","author":"CW Lee","year":"2018","unstructured":"Lee CW, et al. Historical perspectives and advances in mesenchymal stem cell research for the treatment of liver diseases. Gastroenterology. 2018;154(1):46\u201356.","journal-title":"Gastroenterology"},{"issue":"10","key":"3042_CR34","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.stem.2021.09.006","volume":"28","author":"M Krampera","year":"2021","unstructured":"Krampera M, Le Blanc K. Mesenchymal stromal cells: putative microenvironmental modulators become cell therapy. Cell Stem Cell. 2021;28(10):1708\u201325.","journal-title":"Cell Stem Cell"},{"key":"3042_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fbioe.2019.00038","volume":"7","author":"S Fahmy-Garcia","year":"2019","unstructured":"Fahmy-Garcia S, et al. Follistatin effects in migration, vascularization, and osteogenesis in vitro and bone repair in vivo. Front Bioeng Biotechnol. 2019;7:38.","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"3042_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41420-021-00584-z","volume":"7","author":"YH Li","year":"2021","unstructured":"Li YH, et al. Mesenchymal stem cells attenuate liver fibrosis by targeting Ly6C(hi\/lo) macrophages through activating the cytokine-paracrine and apoptotic pathways. Cell Death Discov. 2021;7(1):239.","journal-title":"Cell Death Discov"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-022-03042-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-022-03042-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-022-03042-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T06:47:02Z","timestamp":1660546022000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-022-03042-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3042"],"URL":"https:\/\/doi.org\/10.1186\/s13287-022-03042-4","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"assertion":[{"value":"23 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal study protocols were approved by the Animal Welfare and Ethics Committee of the Fourth Military Medical University (FMMU) and performed in accordance with the \u2018Guidelines for the Care and Use of Laboratory Animals.\u2019","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest with respect to the authorship and publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"403"}}